Enhancing audiometric surveillance in head and neck cancer patients undergoing cisplatin-based chemoradiation

Cisplatin-based chemoradiation remains a cornerstone in the treatment of head and neck cancers (HNCs), but its use is frequently associated with ototoxicity, characterized by high-frequency sensorineural hearing loss, tinnitus, and occasionally vestibular dysfunction. Audiometric monitoring protocols are inconsistently implemented across oncology centres and are often limited to cases in which symptoms have already developed. Early […]